Latest news with #MarcCasper
Yahoo
27-07-2025
- Business
- Yahoo
Thermo Fisher Scientific Inc. (TMO) Has Finally Got It Together, Says Jim Cramer
We recently published . Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the stocks Jim Cramer recently discussed. Thermo Fisher Scientific Inc. (NYSE:TMO) is an American firm that provides equipment to the healthcare and pharmaceutical industries. Its shares have lost 7.5% year-to-date, but would have been down by 22.5% were it not for a massive 19.3% gain in July. Thermo Fisher Scientific Inc. (NYSE:TMO)'s shares soared after the firm raised the lower end of its annual profit per share guidance to $22.22 from $21.76. Cramer praised the firm's earnings report, which included the guidance raise: 'I'm thinking more about Thermo Fisher. And how they finally got it together. Just a gigantic quarter. No longer worried about China. . .But Thermo Fisher is the one that. .Thermo Fisher had also been weak. Congratulations to those guys. They're the first ones to come out of the China conundrum. And the China conundrum is, look we can't, they're not buying our stuff. It's just not any good. They can't get the orders. . .Looks like Thermo Fisher is now past it. Congratulations to Marc Casper, because he's a terrific CEO and it happened. And I think this is the beginning of a big move.' Previously, the CNBC TV host commented on Thermo Fisher Scientific Inc. (NYSE:TMO)'s business and its CEO: 'This stock is unbelievable. It was a, it's a great company. Marc Casper does a terrific job, but we own Danaher for the Charitable Trust, and it's as bad as Thermo Fisher. I am urging you to not buy it till we see a pickup in Chinese orders. I know that seems strange, but this stock has crushed a lot of people. It does seem like it's bottoming, but I am not going to push it because it's related to China, and anything related to China is bearish.' While we acknowledge the potential of TMO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-07-2025
- Business
- Yahoo
TMO Q2 Deep Dive: Pharma Strength, Tariff Adaptation, and Strategic Investments Shape Outlook
Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2025 results beating Wall Street's revenue expectations , with sales up 3% year on year to $10.86 billion. Its non-GAAP profit of $5.36 per share was 2.5% above analysts' consensus estimates. Is now the time to buy TMO? Find out in our full research report (it's free). Thermo Fisher (TMO) Q2 CY2025 Highlights: Revenue: $10.86 billion vs analyst estimates of $10.69 billion (3% year-on-year growth, 1.6% beat) Adjusted EPS: $5.36 vs analyst estimates of $5.23 (2.5% beat) Adjusted EBITDA: $2.61 billion vs analyst estimates of $2.59 billion (24.1% margin, 0.9% beat) Operating Margin: 16.9%, in line with the same quarter last year Organic Revenue rose 2% year on year (-1% in the same quarter last year) Market Capitalization: $176.2 billion StockStory's Take Thermo Fisher's second quarter saw a positive market response, as the company surpassed Wall Street's revenue and adjusted profit expectations. Management attributed the quarter's performance to robust growth in pharma and biotech, especially in bioproduction and Pharma Services, alongside strong execution in their research and safety market channel. CEO Marc Casper emphasized that 'customer uptake is very strong' for the company's Accelerator Drug Development solution, and highlighted sequential improvement in clinical research. However, Casper also noted mid-single-digit declines in academic and government markets, and low single-digit declines in diagnostics and health care, reflecting ongoing hesitancy and demand headwinds in these segments. Looking forward, Thermo Fisher's updated guidance reflects an expectation of gradual improvement in key end markets and ongoing margin expansion through cost management and innovation. Management highlighted strategic priorities such as expanding U.S. manufacturing capacity, integrating Solventum's Purification & Filtration business, and leveraging AI within their PPI Business System to enhance productivity. CFO Stephen Williamson noted, 'We're actively managing the company to appropriately navigate the macro environment,' while Casper outlined a scenario of accelerating growth in 2026 and 2027, anticipating organic revenue growth rising from current levels as academic and government headwinds abate and clinical research builds momentum. Key Insights from Management's Remarks Management attributed the quarter's outperformance to strong pharma and biotech demand, successful cost actions, and resilience in the face of tariffs, while also discussing product innovation and portfolio expansion. Pharma and Biotech Momentum: The company reported mid-single-digit growth in its pharma and biotech end markets, with bioproduction and Pharma Services driving results. Management cited strong customer interest in Accelerator Drug Development, which integrates Pharma Services and clinical research capabilities to reduce drug development time and cost. Academic and Government Weakness: Revenue from academic and government customers declined mid-single digits, with CEO Marc Casper pointing to muted demand and customer caution amid funding uncertainties. Casper indicated this segment is expected to stabilize over time but remains a headwind for now. Tariff Adaptation: Tariffs and related foreign exchange posed a significant headwind, impacting adjusted operating income and margins. Management minimized the impact through operational adjustments and active management, noting that tariff exposure was less severe than previously assumed, particularly in China. Product Innovation and Launches: Thermo Fisher introduced new mass spectrometry and electron microscopy products, including the Astral Zoom and Excedion Pro spectrometers and the Krios 5 cryo-transmission electron microscope. Customer feedback highlighted the potential of these tools to advance precision medicine and biological research. Portfolio and Capacity Expansion: The company amended its acquisition agreement with Solventum to accelerate regulatory clearance and exclude non-synergistic lines, while also announcing an expanded partnership with Sanofi through the acquisition of a sterile fill-finish facility in New Jersey. Management expects these moves to broaden manufacturing capabilities and support customer reshoring efforts. Drivers of Future Performance Thermo Fisher's outlook centers on cost discipline, new product adoption, and recovery in challenged end markets, with ongoing tariff and policy risks. Cost Management and Margin Expansion: Management expects continued productivity gains and cost reductions, leveraging the PPI Business System and AI integration. CFO Stephen Williamson outlined expectations for 50 to 70 basis points of adjusted operating margin expansion annually, even in a muted revenue environment. Recovery in Key Markets: Leadership anticipates that academic and government demand will transition from a headwind to stabilization, while clinical research and pharma services are expected to see improved growth as authorizations and customer activity increase. China remains a near-term headwind but is projected to flatten out over the next two years. Strategic Capital Deployment: The company plans to supplement organic performance with targeted acquisitions and capacity investments, particularly in U.S. manufacturing. The pending Solventum and Sanofi deals are expected to enhance product offerings and meet growing demand for domestic drug production, supporting long-term revenue and profit growth. Catalysts in Upcoming Quarters In the quarters ahead, our analyst team will closely watch (1) the pace of recovery in academic and government demand and whether stabilization emerges, (2) the successful integration and performance of Solventum's Purification & Filtration business and the Sanofi fill-finish facility, and (3) ongoing traction for new analytical instruments and bioproduction solutions. Execution on cost discipline and navigating tariff dynamics will also be key signposts for monitoring Thermo Fisher's ability to deliver on its outlook. Thermo Fisher currently trades at $467.60, up from $426.83 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it's free). Stocks That Trumped Tariffs When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
23-07-2025
- Business
- Yahoo
Thermo Fisher Scientific Stock Jumps on Strong Results, Higher Outlook
Thermo Fisher Scientific (TMO) shares took off after the maker of lab equipment and other life sciences products posted better-than-expected results and boosted its guidance, citing operational improvements and lower expected impacts from new tariffs. The company reported second-quarter adjusted earnings per share (EPS) of $5.36, with revenue rising 3% to $10.85 billion. Both exceeded estimates by analysts surveyed by Visible Alpha. Thermo Fisher attributed the performance to 'active management of our company in the macroenvironment,' pointing specifically to its growth strategy and Practical Process Improvement Business System (PPI). The "agility of our organization, powered by the PPI Business System, allowed us to effectively adapt to current market conditions, actively manage our cost base, and deliver strong operational results,' CEO Marc Casper said. Thermo Fisher updated its full-year adjusted EPS to a range of $22.22 to $22.84 from the previous outlook of $21.76 to $22.84. The tariff situation between the U.S. and China 'has improved significantly versus our prior guidance assumptions,' CFO Stephen Williamson said in a call with analysts, according to a transcript from AlphaSense. Also today, the company announced that Williamson will retire on March 31, 2026. Shares of Thermo Fisher Scientific are up about 12% in midday trading. Despite today's gains, they are down about 8% year-to-date. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Thermo Fisher acquires Sanofi's New Jersey manufacturing site
(Reuters) -Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker. WHY IT'S IMPORTANT Sanofi has been expanding its manufacturing presence in the U.S. market, following efforts from peers such as Roche and Novartis, in a response to President Donald Trump's repeated tariff threats on medicines. Thermo also plans to increase its U.S. manufacturing investments in the range of about $2 billion to mitigate any tariff hit, the company said in April, the company said in April. CONTEXT Under the deal, Thermo will continue manufacturing a portfolio of therapies for Sanofi after the acquisition. The Ridgefield site operates as a sterile fill-finish and packaging facility with more than 200 employees who will join Thermo Fisher. BY THE NUMBERS The companies did not disclose the financial terms of the deal. The transaction is expected to close in the second half of 2025. KEY QUOTE(S) "Sanofi's Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines," said Marc Casper, CEO of Thermo Fisher. WHAT'S NEXT Thermo Fisher said it will strengthen its partnership with Sanofi while investing to expand the Ridgefield site with additional manufacturing capacity. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing resources to domestic operations as ongoing US tariffs risk destabilising global trade. The life sciences giant, which provides products and services to biopharma companies manufacturing drugs, said the $2bn will be invested over the next four years. Thermo Fisher said $1.5bn in capital expenditure would go towards enhancing and expanding US manufacturing operations, whilst the remaining $500m would be directed towards research & development (R&D). There are 64 manufacturing sites operated by Thermo Fisher in the US that provide contract development and manufacturing services for pharmaceutical innovators. Facilities also make analytical instruments, specialty diagnostics and other solutions in the life sciences space. Thermo Fisher did not immediately respond to Pharmaceutical Technology on whether existing sites would benefit from the investment or whether new facilities would be developed over the coming years. Efforts to shore up US manufacturing capabilities come at a time when tariffs announced by US President Donald Trump have made importing into the country less attractive. The government has also threatened tariffs on pharmaceutical imports, an area that previously escaped the blanket levies. The $2bn is a commitment by Thermo Fisher to US manufacturing amid the volatile international trade channels. '[It] reflects our confidence that America will continue to lead the world in science and innovation,' Thermo Fisher's CEO Marc Casper said. 'By expanding our US operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come,' he added. The US expansion is set to counteract headwinds in business operations reported in its Q1 earnings, on 23 April. Thermo Fisher estimates a $400m hit to its sales of products in China this year. Revenue in the country accounts for around 8% of its business. Wall Street was unmoved despite the shaky outlook, with shares in the NYSE-listed company being down by only 0.4% when the markets opened on 24 April following the Q1 earnings report on the previous day. Investor caution was potentially tempered by the $2bn earmarked for US operations. In a Q1 earnings call, chief financial officer Stephen Williamson said sales of the company's US-manufactured products in China would be affected by the ongoing trade disputes. Likewise, the cost of parts manufactured in China, which Thermo Fisher relies on for assembly, would be affected by tariffs. Intuitive Surgical, developer surgical robotic systems, revealed similar impacts in its Q1 report. Thermo Fisher is one of many companies redirecting resources to the US in an effort to make supply chains more robust. Earlier this week, Roche unveiled a $50bn investment strategy to upgrade three R&D sites in the US. Novartis, Johnson & Johnson and Eli Lilly have also made similar investment announcements. The current investment by Thermo Fisher follows $4.1bn spent by the company in February 2025 to acquire Solventum's purification & filtration business unit that has a global footprint, including sites in North America. Not all of Thermo Fisher's US sites have enjoyed investment recently. The company continued its strategic withdrawal from the viral vector manufacturing space in February, cutting headcount at two of its US facilities by 300. Weaker demand for drug manufacturing in recent years has led to several other cost-cutting initiatives, including redundancies at its plasmid manufacturing site in California, the closure of its biologics development and cell therapy services facility in New Jersey, and gene therapy facilities in Florida. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence here. "Thermo Fisher counters tariffs with $2bn investment into US manufacturing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
